Astrazeneca (AZN) Cost of Revenue (2009 - 2026)

Astrazeneca's Cost of Revenue history runs 18 years deep, the most recent figure standing at $2.5 billion for Q2 2026.

• In Q2 2026, Cost of Revenue rose 2.02% year-over-year to $2.5 billion; the TTM figure through Jun 2026 stood at $11.1 billion (up 5.7% YoY), while the FY2025 annual figure was $10.6 billion, up 4.17% from the prior year.
• Cost of Revenue for Q2 2026 stood at $2.5 billion, down from $2.7 billion in the prior quarter.
• The five-year high for Cost of Revenue was $6.0 billion in Q4 2023, with the low at $1.9 billion in Q1 2023.
• The 5-year median for Cost of Revenue is $2.7 billion (2024), against an average of $2.8 billion.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue jumped 138.4% in 2022, then plunged 54.28% in 2024.
• Astrazeneca's Cost of Revenue stood at $2.9 billion in 2022, then surged by 105.52% to $6.0 billion in 2023, then slumped by 54.28% to $2.7 billion in 2024, then grew by 14.42% to $3.1 billion in 2025, then decreased by 19.08% to $2.5 billion in 2026.
• Business Quant data shows AZN's Cost of Revenue at $2.5 billion in Q2 2026, $2.7 billion in Q1 2026, and $3.1 billion in Q4 2025.